|
|
Volumn 30, Issue 8, 2016, Pages 1313-1315
|
|
Early experience of dolutegravir pharmacokinetics in pregnancy: High maternal levels and significant foetal exposure with twice-daily dosing
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR PLUS LAMIVUDINE;
DARUNAVIR PLUS RITONAVIR;
DOLUTEGRAVIR;
EFAVIRENZ;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
LAMIVUDINE PLUS ZIDOVUDINE;
LOPINAVIR PLUS RITONAVIR;
RALTEGRAVIR;
VIRUS RNA;
FUSED HETEROCYCLIC RINGS;
INTEGRASE INHIBITOR;
ADULT;
ANTIVIRAL RESISTANCE;
AREA UNDER THE CURVE;
B LYMPHOCYTE;
BACTEREMIA;
CASE REPORT;
CD4 LYMPHOCYTE COUNT;
CESAREAN SECTION;
DRUG BLOOD LEVEL;
DRUG PROTEIN BINDING;
DRUG TOLERABILITY;
EX VIVO STUDY;
FEMALE;
FOLLOW UP;
GENOTYPE;
GESTATIONAL AGE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN X4);
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
HYDRONEPHROSIS;
IC90;
LETTER;
LUNG EMBOLISM;
MATERNAL BLOOD;
MAXIMUM PLASMA CONCENTRATION;
NONHUMAN;
PATIENT COMPLIANCE;
PLACENTAL TRANSFER;
PRACTICE GUIDELINE;
PREGNANCY;
PRENATAL DRUG EXPOSURE;
PRIORITY JOURNAL;
REBOUND;
THIRD TRIMESTER PREGNANCY;
UMBILICAL CORD BLOOD;
VIRUS LOAD;
YOUNG ADULT;
DOSE RESPONSE;
DRUG EFFECTS;
FETOMATERNAL TRANSFUSION;
FETUS BLOOD;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NEWBORN;
PREGNANCY COMPLICATION;
PREGNANCY OUTCOME;
PRENATAL EXPOSURE;
PROTOCOL COMPLIANCE;
ADULT;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
FETAL BLOOD;
GUIDELINE ADHERENCE;
HETEROCYCLIC COMPOUNDS, 3-RING;
HIV INFECTIONS;
HIV INTEGRASE INHIBITORS;
HUMANS;
INFANT, NEWBORN;
MATERNAL-FETAL EXCHANGE;
PREGNANCY;
PREGNANCY COMPLICATIONS, INFECTIOUS;
PREGNANCY OUTCOME;
PRENATAL EXPOSURE DELAYED EFFECTS;
YOUNG ADULT;
|
|
EID: 84966430634
PISSN: 02699370
EISSN: 14735571
Source Type: Journal
DOI: 10.1097/QAD.0000000000001055 Document Type: Letter |
|
Times cited : (13)
|
|
References (7)
|
